HDAC8 (histone deacetylase 8) has been shown to restore the effector functions of CD8+ T cells, thereby enhancing the therapeutic effects of anti-PD-1 treatment in NSCLC (91). The gene discussed is HDAC8; the disease is non-small cell lung carcinoma.